

## Special Issue

# Obstructive Sleep Apnea (OSA): Pathogenesis, Symptoms and Treatments

### Message from the Guest Editor

Obstructive sleep apnea (OSA) is a common respiratory sleep disorder characterized by episodes of complete/partial upper airway collapse together with airflow reduction or cessation. OSA is associated with systemic organ damage, such as heart failure, diabetes mellitus and cognitive dysfunction. Thus, efforts aiming to define the symptoms and clarify the pathogenesis of OSA are essential for the exploration of new treatments. This Special Issue of the *Journal of Personalized Medicine* aims to highlight some of the latest studies on the pathogenesis, symptoms and treatment of OSA and the application of precision medicine to patients with OSA.

### Guest Editor

Dr. Huajun Xu

1. Department of Otorhinolaryngology Head and Neck Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, China
2. Shanghai Key Laboratory of Sleep Disordered Breathing, 600 Yishan Road, Shanghai, China
3. Otolaryngology Institute of Shanghai Jiao Tong University, 600 Yishan Road, Shanghai, China

### Deadline for manuscript submissions

closed (25 June 2023)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/152926](https://mdpi.com/si/152926)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).